Effect of Beta Particles Spectrum on Absorbed Fraction in Internal Radiotherapy

Marjan Hashempour\textsuperscript{1}, Mahdi Ghorbani\textsuperscript{2*}, Ernesto Amato\textsuperscript{3}, Courtney Knaup\textsuperscript{4}

\textsuperscript{1} Physics Group, Faculty of Basic Sciences, Hakim Sabzevari University, Sabzevar, Iran
\textsuperscript{2} Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
\textsuperscript{3} Department of Biomedical and Dental Sciences and of Morphofunctional Imaging, University of Messina, Messina, Italy
\textsuperscript{4} Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA

\section*{ARTICLE INFO}

\textbf{Article type:} Original article

\textbf{Article history:}
Received: 06 May 2018
Revised: 11 Aug 2018
Accepted: 25 Aug 2018

\textbf{Keywords:}
Absorbed fraction
Analytical function
Beta emitters
Internal radiotherapy
Monte Carlo simulation

\section*{ABSTRACT}

\textbf{Objective(s):} The purpose of this research is to study the effect of beta spectrum on absorbed fraction ($\phi$) and to find suitable analytical functions for beta spectrum absorbed fractions in spherical and ellipsoidal volumes with a uniform distribution for several radionuclides that are commonly used in nuclear medicine.

\textbf{Methods:} In order to obtain the beta particle absorbed fraction, Monte Carlo simulations were performed by using the MCNPX code. The validation of the simulations was performed by calculating the absorbed fractions in spheres and comparing the results with the data published by other investigators. The absorbed fractions were calculated and compared by using an actual beta energy spectrum with those obtained through the mean beta energy of $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{153}$Sm, $^{186}$Re, $^{32}$P, $^{90}$Sr, $^{131}$I, $^{90}$Y, $^{88}$Rb radionuclides.

\textbf{Results:} The maximum difference between the absorbed fractions for beta particles accounting for the whole beta spectrum of all the considered nuclides was 29.62\% with respect to the mean beta energy case. Suitable analytical relationships were found between the absorbed fraction and the generalized radius, and the dependence of the fitting parameters from beta spectrum energy was discussed and fitted by appropriate parametric functions.

\textbf{Conclusion:} The results allowed the calculation of the absorbed fractions from the above stated beta sources uniformly distributed in spherical and ellipsoidal volumes of any ellipticity and volume, in a wide range of practical volumes that are not only used for internal dosimetry in nuclear medicine applications, but also in radiological protection estimates of doses from internal contamination.

\textsuperscript{*} Corresponding author: Mahdi Ghorbani, Biomedical Engineering and Medical Physics Department, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Velenjak, Tehran, Iran. Tel: +982123872566; Email: mhdghorbani@gmail.com

© 2019 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Beta-emitting radionuclides are extensively used for the treatment of tumors and various diseases in the form of internal radiotherapy as well as for tumor imaging (1). Radiopharmaceuticals labeled with 177Lu, 131I, 90Sr, 153Sm, 186Re, 32P, and 90Y are used for the treatment of various types of cancers such as the palliation of bone metastases and ocular surface tumors, liver tumors, breast cancer, and for metastatic prostate cancer (2-8). The knowledge of radiation absorbed fraction, i.e. the fraction of emitted energy which is absorbed within the target volume, is an essential issue for both radionuclide internal dosimetry and radiological protection (9).

In the approach presented by the Medical Internal Radiation Dose (MIRD) Committee, beta absorbed fraction is considered equivalent to unity in large organs, but in smaller regions, it is less than unity and differs depending on the size and the geometry of the target organ (10). The absorbed fraction tends to be unity when the target dimensions are greater than the range of the beta emitted by the source. On the other hand, when this condition is not satisfied the absorbed fraction may be lower and its dependence on the target dimensions and beta energy cannot be overlooked (11).

In nuclear medicine, the absorbed fraction is an important parameter for calculating the absorbed dose. One of the factors that affect the absorbed fraction is the energy emitted by the source. In dosimetric calculations with commercially available software (12), only the monoenergetic spectrum may be taken into account. When the monoenergetic beta spectrum is used, the quantity of the energy absorbed by the target differs from the actual value (11). This causes discrepancies in dose calculation. Since the adopted criteria in nuclear medicine planning are based on tolerance doses, it highlights the importance of critical organ doses that must be estimated accurately.

A number of the pamphlets published by the MIRD committee have made wide use of the Monte Carlo simulation to calculate the absorbed fractions for beta emitting sources uniformly distributed in organs. Akabani et al. (11) estimated the beta absorbed fractions in small spherical volumes of tissue for a number of radionuclides by using mean energy and the entire beta spectrum. They showed that for volumes with radii greater than the range of the electrons, the use of mean beta energy of the beta spectrum gave a good approximation to the absorbed fraction, when compared to the results acquired by the extended beta spectra of the radionuclides. Additionally, they found the absorbed fractions in the source region for various radionuclides as a function of the surface-to-volume ratio.

A spherical model is employed to model nodules and other small regions in human dosimetry, as well as for whole non-human organisms in an environmental radioactivity pollution assessment. Additionally, generalization to ellipsoids is favorable, when the assumption of a spherical shape for an ellipsoidal structure leads to accurate dosimetric evaluations of the order of several percent, depending on the dimensions, the degree of non-sphericity, and the radionuclide emission spectrum. Amato et al. (13) used the Gant4Monte Carlo code to calculate the absorbed fractions for uniformly distributed 198Au, 177Lu, 131I, 153Sm, 186Re and 90Y beta emitters, using proper extended beta energy spectra in ellipsoidal volumes of soft tissue. They proved that the absorbed fraction was a function of the generalized radius and calculated the \( \rho_0 \) and \( s \) parameters of the analytical fit for each radionuclide. Based on the results, \( \rho_0 \) (the cut-off radius) was approximately proportional to the average beta energy of the radionuclide, but there was no relationship between the exponential term \( s \) and the average beta energy. They presented a mean value of 1.13 for the \( s \) parameter for radionuclides that were different from those included in their study. Subsequently, Amato et al. (9) calculated the absorbed fractions inhomogeneous ellipsoid volumes made from soft tissue by considering monoenergetic electrons of 10 energies: 10, 20, 50, 70, 100, 200, 500, 700, 1000 and 2000 keV. They introduced analytical functions for the relationship between \( s \) and \( \rho_0 \) and the mean electron energy. They showed that dose calculation in the case of extended beta spectra can be evaluated through integration. In another study, Mowlavi et al. (10), based on Monte Carlo simulations with MCNP code, found analytical functions for the beta and gamma absorbed fractions of 131I in spherical and ellipsoidal volumes of soft tissue.

The MIRD method for dose calculation can be used when the source organ and the target organ are different from each other or when they are the same (10). The present study investigates the effect of discrete spectrum of beta emitters on the absorbed fraction. Furthermore, suitable
analytical functions are found for the absorbed fractions obtained by the application of beta discrete spectrum in spherical and ellipsoidal volumes with the uniform distribution of $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{196}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb radionuclides, when these volumes are defined as sources.

**Methods**

The influence of the discrete spectral definition of beta energy on the absorbed fraction was evaluated when the source organ coincided with the target organ. Absorbed fractions (self-absorption) were calculated for $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{196}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb beta emitter radionuclides, uniformly distributed in spherical and ellipsoidal volumes of soft tissue. The beta energy discrete spectra of these radionuclides are illustrated in Figure 1 (14). Soft tissue with a density of 1.04 g/cm$^3$ was adopted as the constituent material of all the target volumes (15).

All the simulations were performed by the MCNPX (version 2.7.0) Monte Carlo code. In the first part of this investigation, the validation of the simulations was performed by calculating the absorbed fraction of $^{90}$Y radionuclide with volumes ranging from 0.004 cm$^3$ to 100 cm$^3$ in spherical volumes and by comparing the results

*Figure 1. Energy spectrum, minimum, maximum and mean energy of beta particles for $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{196}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb radionuclides (14)*
with the data published by other investigators (11, 13). During the validation step, the volumes of the spheres were rounded up to one decimal point. These validations were performed only for $^{90}$Y because there was no detailed data on the absorbed fraction for other beta emitter radionuclides. In the second part of this investigation, the absorbed fractions obtained by applying the average and the discrete spectral beta energies in spherical and ellipsoidal volumes for $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{152}$Sm, $^{38}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb radionuclides were calculated and the results were compared with each other. Finally, suitable analytical functions for the beta discrete spectrum absorbed fractions were presented.

**Validation of Monte Carlo simulations**

The validation of the Monte Carlo simulations was performed by calculating the absorbed fraction obtained by the average and the discrete spectrum beta particles of $^{90}$Y radionuclide in spherical volumes and comparing the results with the data previously published by Akabani et al. (11) and Amato et al. (13). For this purpose, spheres with volumes ranging from 0.004 cm$^3$ to 100 cm$^3$ were simulated and the *F8 tally was scored. The *F8 tally considers the energy deposition of particles on their transport path when photons and electrons interact with matter, rather than the instantaneous energy deposition at the position of the interaction. The simulations were performed for up to $10^6$ particle histories. In these calculations, the energy cut off was 1 keV for beta particles.

**Effect of discrete spectral definition of beta energy on absorbed fraction**

According to the MIRD approach, the mean absorbed dose from a monoenergetic emission of a radiation $j$ to the target volume is calculated as:

$$D_j = \frac{\bar{A}}{m} \int_0^{E_M} \frac{dn(E)}{dE} E\phi(E) dE$$

(1)

Where $\bar{A}$ is the time-integrated activity (Bq); $m$ is the target mass (in terms of g or kg), $E$ is the particle energy (MeV), $n$ is the emission probability per disintegration, and $\phi$ is the absorbed fraction (16).

The absorbed fraction ($\phi$) depends on the emission type, energy, and also the geometry and the specification of the source and the target tissue. These factors used for dose calculation when either the source organ is different from the target organ (i.e. cross-organ dose) or when they are the same (i.e. self-dose) (17). The dose for an extended beta spectrum is obtained by the following integration:

$$D = \bar{A} \int_0^{E_M} \frac{dn(E)}{dE} E\phi(E) dE$$

(2)

Where $E$ is the particle energy, $dn/dE$ is the differential emission probability of the radionuclide and $E_M$ is the most probable energy emitted. For the determination of the absorbed fraction by the entire beta spectrum by, using the *F8 tally, nine volumes ranging from 0.01 cm$^3$ to 250 cm$^3$ were simulated. Each volume had a different geometry: spherical, prolate ellipsoid with $(a=b, c)$ and oblate ellipsoid with $(a=b=2c)$, where $a$, $b$ and $c$ are the coordinate axes. The prolate ellipsoid with $(a=b, c)$ and the oblate ellipsoid with $(a=b=2c)$ are illustrated in Figure 2. It should be noted that in this study, discrete spectrum was used for beta particles.

The physical characteristics, including elemental compositions and densities, of the soft tissue used in these simulations are listed in Table 1. The absorbed fraction was assessed by using the following equation:

$$\phi = \frac{E_b}{E_t}$$

(3)

$E_b$ is the energy of the beta particle absorbed in the target and $E_t$ is the energy of the beta particle. To compare the absorbed fractions of the various radionuclides as a function of the target dimension, for a generic ellipsoidal shape, the "generalized radius" is defined as (13):

$$\rho = \frac{V}{S}$$

(4)

Where $V$ is the target volume and $S$ is its surface. For ellipsoidal shapes, $V$ and $S$ are obtained from:

$$V = \frac{4}{3}\pi abc \text{ and } S \approx 4\pi\left(\frac{ab+p+ac+p+bc+p}{3}\right)^{\frac{3}{2}}$$

(5)

Where $p \approx 1.6075$, and $a$, $b$ and $c$ are the semi-axes. For a sphere, the generalized radius is equal to the radius of the sphere.

In the present study, a new relationship was proposed between $\phi$ and $\rho$, by fitting the $\phi (\rho)$ graph versus $\rho$:

$$\phi = (1 + \frac{\rho_0}{\rho})^{-1} - \rho$$

(6)
The $s$, $\rho_0$, and $p$ parameters are the fitting parameters. The fittings were performed by using MATLAB (The Math Works, Inc. Corporation, Version R 2015 b).

In 2000, FDA (the U.S. Food and Drug Administration) rewrote the MIRDose code in order to increase the accuracy in dosimetric calculations. This new code was renamed OLINDA/EXM (18). It is employed in nuclear medicine departments for standardization and automation of internal dose calculations. The OLINDA/EXM code includes a sphere model that assumes isolated unit density (19).

In the present study, the OLINDA/EXM sphere model was run for three nuclides of $^{32}$P, $^{90}$Y, and $^{38}$Cl and a non-linear interpolation was made between the values in order to determine the OLINDA/EXM estimations at the exact volumes. Then, the analytical method provided in this paper was implemented on an electronic spreadsheet for the three nuclides, and self-doses were determined for the same spheres. The calculation were based on the spectra taken from the database by RADAR working group (20), which has the same reference as that of the OLINDA/EXM software.

**Results**

Table 2 presents the comparison of the absorbed fractions related to the mean and discrete spectral beta energies for $^{90}$Y radionuclide in the spheres obtained in this study with the results published in previous studies (11, 13). The deviation between the absorbed fraction values, $\sigma$ (%), is defined as:

$$\sigma = 100 \times (\phi - \phi_{\text{Ref}})$$  \hspace{1cm} (7)

The differences in the absorbed fractions for $^{90}$Y radionuclide between the present study and previous studies ranged from 1.00% to 5.00%. For the purpose of comparison, the absorbed fractions obtained by the average energy and the discrete spectrum energies in spherical and ellipsoidal volumes with a uniform distribution of $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{186}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb radionuclides are presented in Table 3 (the differences ranged from 1.20% to 29.62%) and shown as a function of the generalized radius.
Table 2. Absorbed fractions for $^{90}$Y radionuclide in this study and from previous studies

| Volume (cm$^3$) | Radius (cm) | Beta absorbed fractions (σ) | By mean beta energy |
|----------------|-------------|-----------------------------|---------------------|
|                |             | This work | Previous study (Reference) | σ(%) |
| 0.004          | 0.10        | 0.15     | 0.16 (Akabani et al. [11]) | -1.00 |
| 0.065          | 0.25        | 0.45     | 0.48 (Akabani et al. [11]) | -3.00 |
| 4              | 1.00        | 0.84     | 0.86 (Akabani et al. [11]) | -2.00 |

Table 3. Absorbed fractions obtained by mean beta energy and spectral beta energies in spherical and elliptical volumes for $^4$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{152}$Sm, $^{188}$Re, $^{32}$P, $^{90}$Y, $^{86}$Cd and $^{88}$Rb radionuclides

| Volume (cm$^3$) | Energy | Spectrum | Mean | σ(%) |
|----------------|--------|---------|------|------|
|                 | 0.01   | 0.1     | 0.01 | 0.01 |
|                 | 0.02   | 0.02    | 0.01 | 0.01 |
|                 | 0.03   | 0.03    | 0.01 | 0.01 |
|                 | 0.04   | 0.04    | 0.01 | 0.01 |

Asia Ocean J Nucl Med Biol. 2019; 7(1): 71-83.
\( \rho \) in Figure 3. For all the radionuclides, these data were obtained from spherical, oblate and prolate ellipsoidal shapes. In Figure 3, the solid lines represent the analytical fitting of each data series with the function presented in Equation (6). In Table 4, the \( s, \rho \), and \( p \) fitting parameters are presented for each radionuclide. The linear regression \( R^2 \) and the sum of SSE values are listed in Table 4, and these results demonstrate the goodness of fitting.

In Figure 4, the parameters \( s, \rho \), and \( p \) are plotted as function of the radionuclide mean beta energy. The linear regression, \( R^2 \), and SSE values are also mentioned in this figure.

Table 5 presents the absorbed doses for \( ^{14}C, ^{199}Au, ^{177}Lu, ^{131}I, ^{90}Sr, ^{153}Sm, ^{186}Re, ^{32}P, ^{88}Y \) and \( ^{88}Rb \) radionuclides calculated by Equations (2) and (6). Then these results are compared with the results obtained from the equations presented by Amato et al. (9). It can be seen that the maximum differences between the results of beta absorbed fraction obtained from this study and the equations presented by Amato et al. (9) are 11.11%, 24.17% and 93.36% for the 753.97, 67.03 and 6.27 cm\(^3\) volumes, respectively. The main differences found were subjected to a further comparison with respect to the reference values calculated by the means of the sphere model contained in the OLINDA/EXM software (19). The comparison of the results of beta absorbed dose from this study and those by Amato et al. (13) and the OLINDA sphere model for \( ^{32}P, ^{88}Y, ^{38}Cl \) in 6.28 and 67.02 cm\(^3\) volumes are listed in Table 6. The differences in the self-
Figure 3. Absorbed fractions as a function of generalized radius obtained by spectral beta energies for various radionuclides

Table 4. s(E), $\rho_0(E)$ and $\rho(E)$ fitting parameters, $R^2$ and SSE values obtained from equations (6) and equations presented by Amato et al. [9]

| Fitting parameters | Equations (6) and equations presented by Amato et al. [9] | $^{14}$C | $^{38}$Au | $^{90}$Y | $^{32}$P | $^{186}$Re | $^{153}$Sm | $^{90}$Sr | $^{131}$I | $^{177}$Lu | $^{199}$Au | $^{14}$C |
|--------------------|----------------------------------------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| s(E)               | $\phi(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 1.057   | 1.024   | 1.084   | 1.118   | 1.125   | 1.143   | 1.242   | 1.247   | 1.218   | 1.164   | 1.139   |
|                    | $\phi_0(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 0.087   | 0.171   | 0.348   | 0.394   | 0.516   | 0.539   | 1.136   | 0.984   | 1.043   | 1.059   | 1.141   |
| $\sigma$ (%)       | 97.00 | 85.30   | 73.60   | 72.40   | 61.20   | 60.60   | 10.60   | 26.30   | 17.80   | 18.50   | 0.10    |
| $\rho_0(E)$        | $\phi(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 0.003   | 0.010   | 0.019   | 0.025   | 0.027   | 0.034   | 0.061   | 0.137   | 0.226   | 0.752   | 0.849   |
|                    | $\phi_0(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 0.087   | 0.148   | 0.132   | 0.169   | 0.121   | 0.156   | 0.079   | 0.275   | 0.420   | 0.848   | 0.968   |
| $\sigma$ (%)       | -5.70 | -13.80  | -11.30  | -14.40  | -9.40   | -12.20  | -1.80   | -13.80  | -19.40  | -19.40  | -9.60   | -11.90  |
| $\rho(E)$          | $\phi(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 0.999   | 0.999   | 0.999   | 0.999   | 0.999   | 0.999   | 0.999   | 0.999   | 0.999   | 0.998   | 0.999   |
|                    | $\phi_0(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 0.853   | 0.885   | 0.916   | 0.9202  | 0.945   | 0.945   | 0.986   | 0.990   | 0.998   | 0.998   | 0.998   |
| $\sigma$ (%)       | -0.74 | -0.104  | -0.084  | -0.101  | -0.069  | -0.088  | -0.102  | -0.070  | -0.069  | -0.022  | -0.024  |
| $\beta'$           | $\phi(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 1.8×10^{-3} | 3.5×10^{-4} | 4.6×10^{-5} | 7.7×10^{-6} | 2.8×10^{-7} | 1.7×10^{-8} | 8.9×10^{-8} | 1.5×10^{-8} | 9.0×10^{-8} | 2.6×10^{-8} | 1.9×10^{-8} |
|                    | $\phi_0(p) = \left(1 + \frac{\rho}{\rho_0}\right)^{1-p}$ | 2.5×10^{-4} | 1.8×10^{-4} | 4.8×10^{-5} | 8.2×10^{-6} | 6.7×10^{-7} | 1.0×10^{-7} | 1.1×10^{-7} | 1.5×10^{-7} | 1.4×10^{-7} | 3.3×10^{-8} | 3.0×10^{-8} |
| $\sigma$ (%)       | -11.90 | -9.60   | -19.40  | -13.80  | -1.80   | -13.80  | -19.40  | -9.60   | -11.90  |

dose results between the present study and this software were in the range of 0.67% to 5.11%, except for the highest energy nuclide ($^{38}$Cl) in 6.283 cm$^3$ volume.
Figure 4. Fitting of (a) $s(E)$, (b) $\rho_0(E)$ and (c) $p(E)$ as function of radionuclide’s mean energy.
Table 5. Comparison of the results of beta absorbed dose from this study and those by equations presented by Amato et al. (9)

| Radionuclide | Absorbed dose (µGy/MBq) | This study | Equations presented by Amato et al. | Diff. (%) | This study | Equations presented by Amato et al. | Diff. (%) |
|--------------|--------------------------|------------|-------------------------------------|-----------|------------|-------------------------------------|-----------|
|              | Volume=753.97 (cm³)      |            |                                     |           | Volume=67.03 (cm³) |                                      |           |
| 14C          | 0.021                    | 0.023      | -8.69                               |           | 0.237      | 0.259                               | -8.49     | 2.527 | 2.706 | -6.61 |
| 199Au        | 0.016                    | 0.018      | -11.11                              |           | 0.182      | 0.200                               | -9.00     | 1.941 | 2.123 | 8.57 |
| 177Lu        | 0.225                    | 0.227      | -7.41                               |           | 0.277      | 0.305                               | -9.18     | 2.959 | 3.212 | -7.87 |
| 131I         | 0.034                    | 0.037      | -8.11                               |           | 0.378      | 0.415                               | -8.91     | 4.037 | 4.341 | -7.00 |
| 90Sr         | 0.036                    | 0.040      | -10.00                              |           | 0.407      | 0.447                               | -8.94     | 4.346 | 4.673 | -6.99 |
| 153Sm        | 0.042                    | 0.046      | -8.69                               |           | 0.473      | 0.518                               | -8.68     | 5.050 | 5.368 | -5.92 |
| 186Re        | 0.061                    | 0.067      | -8.95                               |           | 0.682      | 0.738                               | -7.58     | 7.278 | 7.450 | -2.31 |
| 32P          | 0.128                    | 0.140      | -8.57                               |           | 1.441      | 1.507                               | -4.37     | 15.376 | 14.102 | 9.03 |
| 90Y          | 0.172                    | 0.185      | -7.02                               |           | 1.938      | 1.948                               | -0.51     | 20.675 | 17.024 | 21.44 |
| 38Cl         | 0.282                    | 0.285      | -1.05                               |           | 3.177      | 2.689                               | 18.15     | 33.897 | 19.584 | 73.08 |
| 88Rb         | 0.381                    | 0.377      | -1.06                               |           | 4.285      | 3.451                               | 24.17     | 45.714 | 23.641 | 93.36 |

Table 6. Comparison of the results of beta absorbed dose from this study and those by equations presented by Amato et al. (9) and from OLINDA/EXM software (sphere model) for 32P, 90Y, 38Cl in 6.28 cm³ and 67.02 cm³ volumes

| Radionuclide | Absorbed dose (µGy/MBq) | This study | OLINDA | Diff. (%) | equations presented by Amato et al.[9] | OLINDA | Diff. (%) |
|--------------|--------------------------|------------|--------|-----------|----------------------------------------|--------|-----------|
|              | Volume=67.02 cm³         |            |        |           |                                        |        |           |
| 38Cl         | 3.18                     | 3.33       | -4.50  | 2.69      | 3.33                                   | -19.21 |
|              | Volume=6.28 cm³          |            |        |           |                                        |        |           |
| 32P          | 15.38                    | 16.20      | -5.11  | 14.10     | 16.20                                  | -12.96 |
| 90Y          | 20.67                    | 20.81      | -0.67  | 17.02     | 20.81                                  | -18.21 |
| 38Cl         | 33.20                    | 28.40      | 16.90  | 19.58     | 28.40                                  | -31.05 |

Discussion

In the present study, the effect of the beta spectrum on the absorbed fraction (self-absorption) was quantified for several radionuclides that are commonly used in nuclear medicine. Then, suitable analytical functions were found for the beta energy spectrum absorbed fractions in spherical and ellipsoidal volumes with uniform distribution of 14C, 199Au, 177Lu, 131I, 90Sr, 153Sm, 186Re, 32P, 90Y, 38Cl and 88Rb radionuclides. The validations of the simulations were based on a comparison of the simulated beta absorbed fraction for 90Y radionuclide in spheres with the data previously published by Akabani et al. (11) and Amato et al. (9-13) for the mean and the spectrum energy. As per the data presented in Table 2, the maximum differences in the absorbed fractions for 90Y radionuclide between the present study and the previous studies are 3.00% and 5.00% for the mean and the spectrum energy, respectively. Generally, these results are in good agreement with the reported data of the previous studies (9-11). The absorbed fraction depends on the size and the geometry of the source, the distribution of the radioactive material, the type of the emitted radiations, and the energies emitted by the radionuclide (11). Any change in each of these parameters will change the amount of the absorbed fraction. In the present study, the same size and geometry for the source and the distribution of radioactive material was used as they were described in previous studies (9-13).
However, they were not used for the same energy spectra and this could be one of the reasons for the differences between the data presented in the present study and those in the previous studies. Phantom included separate spheres of volumes ranging from 0.004 cm$^3$ to 100 cm$^3$. Another reason for the differences observed in these data can be due to the differences in the Monte Carlo codes. According to the results presented by previous literature, the difference between the absorbed fractions of beta from the different versions of Monte Carlo codes ranged from 2.00% to 3.00% for low-energy and 10% for high-energy beta particles (21). This may be due to the different cross-section libraries for the various electron interactions and the different electron transport algorithms that are used in different codes.

Table 3 indicates the importance of considering the beta spectrum as opposed to using the average beta energy in dosimetric calculations due to the differences in the calculated absorbed fractions. According to these results, the differences between the absorbed fractions from the mean and the spectrum beta energy for beta emitted by $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{186}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb ranged ranging from 1.20% to 29.62%. The maximum type A uncertainty in the Monte Carlo calculations in this step was 3.00%; this difference level between these two data series indicates the discrepancy in the calculation of the absorption fraction by applying the mean beta energy.

The absorbed fraction can be defined as the fraction of the energy emitted in the source volume that was absorbed in the target volume (10). The beta particle interacts with the atoms of the material through inelastic collisions with atomic electrons (excitation and ionization), elastic scattering by nuclei, bremsstrahlung and emission of Cherenkov radiation depending on their energy. Due to the continuous energy distribution of the beta particles, the absorption of the beta particles in the material is also continuous (22). When the monoenergetic electrons interact with the matter, bremsstrahlung and excitation interactions occur with rates that depend on the electron energy. On the other hand, when poly-energetic beta particles interact with the atoms, the probabilities of various interactions vary with the particle energy. The use of either mean or mono-energy spectrum for the beta particles can have an effect on the absorbed fraction results and therefore on the absorbed dose (10). This is because the cross-sections of different electron collisions depend on the radiant energy of the radionuclide. According to the results of the present study, considerable differences were observed between the absorbed fractions obtained by the mean energy and the discrete spectrum energies.

The information presented in Figure 3 shows that for each radionuclide analyzed and for each geometrical configuration (sphere, oblate ellipsoid, and prolate ellipsoid), the absorbed fraction is a function of the generalized radius. The perceivable dependence of $\phi$ on $\rho$ is due to the fraction of the beta particles escaping from the target volume, and this fraction depends on the volume-surface ratio (9-13).

Amato et al. (9-13) suggested an analytical function for the relationship between the absorbed fraction and the generalized radius ($\rho$), providing the parameters for some extended beta spectra that are commonly employed in nuclear medicine ($^{199}$Au, $^{177}$Lu, $^{131}$I, $^{153}$Sm, $^{186}$Re and $^{90}$Y) as reference (13) and then extending their analytical formalism to a generic beta spectrum through integration (9). Regarding the nuclides considered in the present study, i.e., $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{186}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb, the differences between the $\rho_0$ and $s$ fitting parameters obtained from Equation (6) and the equations presented by Amato et al. (9) are presented in Table 4. The linear regression, $R^2$, and SSE values are also presented in this table. According to the data provided for $R^2$ and SSE, it can be concluded that the linear fitting function in Equation (6) is a more accurate choice for calculating the absorbed fraction of the beta spectrum.

Figure 4 shows no constant relationship between the exponent sand $p$, and the beta energy of the radionuclides. On the contrary, $\rho_0$ is proportional to the beta energy of the radionuclide. In order to calculate the absorbed fraction by spectral energies there is a need to calculate $s$, $\rho_0$ and $p$ from the equations shown in Figure 4.

The absorbed fraction can be obtained for each generalized radius by substituting $s$, $\rho_0$ and $p$ in Equation (6). And finally, the absorbed dose can be calculated by Equation (2). Table 5 presents the results of the comparison between radiation absorbed doses calculated by means of our analytical approach, and the tabular values obtained from the analytical approach presented by Amato et al. (9) for $^{14}$C, $^{199}$Au, $^{177}$Lu, $^{131}$I, $^{90}$Sr, $^{153}$Sm, $^{186}$Re, $^{32}$P, $^{90}$Y, $^{38}$Cl and $^{88}$Rb radionuclides. These data are related to volumes of 753.984 cm$^3$, 67.021 cm$^3$, and 6.283 cm$^3$. According to this table, the relative difference of the absorbed doses between the present study and the previous
The present study evaluated the influence of the discrete spectral definition of beta energy on the absorbed fraction. In all the steps of the calculations, the spectrum was considered for beta particles, except for the fitting parameters, for which the mean energy was considered for the beta particles. For future studies, it is suggested that the spectrum beta should be used for all the steps, including the fitting process. In this study a discrete spectrum was applied for the beta particles of various radionuclides. To increase the accuracy in calculating the absorbed dose, it is recommended that a continuous spectrum should be used for the beta particles and this may be a subject for further research in this field.

Conclusion

This work developed a new analytical model, which enables more accurate calculations of the absorbed fractions for beta emitting radionuclides. The results obtained from the validations of the simulations were in good agreement with the data reported in previous studies. Moreover, the agreement between this study and the OLINDA/EXM data once again demonstrated the validity of the results of the present analytical model.

The International Commission on Radiation Units and Measurements (ICRU) in report No. 24 recommended that the uncertainty in radiation dose delivery in radiotherapy should be in the range of ±5% (23). Based on the results of this study, the differences between the calculated absorbed fraction by average and spectrum beta energies ranged from 0.120% to 29.62%. Therefore, the impact of the spectral energy on the absorbed fraction on the MIRD formulas should be corrected in order to minimize the total uncertainty in dose delivery in internal radiotherapy.

The use of the analytical formulas presented for the absorbed fraction as a function of the generalized radius, and the parametric functions for $\rho_0(E)$, $s(E)$ and $p(E)$, enables a detailed calculation of the absorbed dose for the whole energy range of practical interest for internal dosimetry in nuclear medicine therapeutic applications and radiological protection estimations of doses from internal pollutions. The parameters in the presented formulas depend on the radiation energy spectrum and the radionuclide energy.

Acknowledgements

The authors would like to thank Shahid Beheshti University of Medical Sciences for financial support of this work.

Conflicts of interest

The authors declare that they have no conflict of interest. This study does not contain any evaluation with human participants or animals performed by any of the authors.

References

1. Siegel JA, Stabin MG. Absorbed fractions for electrons and beta particles in spheres of various sizes. J Nucl Med. 1994;35(1):152-6.
2. Salek N, Shamsaei M, Ghanadi Maragheh M, Shirvani Arani S, Bahrami Samani A. Production and quality control $^{177}$Lu (NCA)-DOTMP as a potential agent for bone pain palliation. J Appl Clin Med Phys. 2016;17(6):128-39.
3. Jalili AR, Biki D, Hassanazadeh-Rad A, Eftekhari A, Geramifar P, Eftekhari M. Production and clinical applications of radiopharmaceuticals and medical radioisotopes in Iran. Semin Nucl Med. 2016;46(4):340-58.
4. Cohen VM, Papastefanou VP, Liu S, Stoker I, Hungerford JL. The use of strontium-90 Beta radiotherapy as adjuvant treatment for conjunctival melanoma. J Oncol. 2013;2013:349162.
5. Andreou M, Lagopati N, Lyra M. Re-186 and Sm-153 dosimetry based on scintigraphic imaging data in skeletal metastasis palliative treatment and Monte Carlo simulation. J Phys Conf Ser. 2011;317(1):012013.
6. Tu SM, Lin SH, Podoloff DA, Loqothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol.

Asia Ocean J Nucl Med Biol. 2019; 7(1): 71-83.
7. Stank J, Melichar F, Filyanin AT, Tomes M, Beran M. Preparation of $^{90}$YCl$_3$ radiopharmaceutical precursor for nuclear medicine using technology of centrifugal extractors. Appl Radiat Isot. 2010;68(12):2163-8.

8. Naseri Z, Hakimi A, Jallilian AR, Nemati Khart A, Bahrami-Samani A, Ghannadi-Maragheh M. Preparation and quality control of the $[^{153}$sm]-samarium maltolate complex as a lanthanide mobilization product in rats. Sci Pharm. 2011;79(2):265-75.

9. Amato E, Lizio D, Baldari S. Absorbed fractions for electrons in ellipsoidal volumes. Phys Med Biol. 2011;56(2):357-65.

10. Mowlavi AA, Fornasier MR, Mizaey M, Brequant P, de Denaro M. Analytical functions for beta and gamma absorbed fractions of iodine-131 in spherical and ellipsoidal volumes. Ann Nucl Med. 2014;28(8):824-8.

11. Akabani G, Poston JW Sr, Bolch WE. Estimates of beta absorbed fractions in small tissue volumes for selected radionuclides. J Nucl Med. 1991;32(5):835-9.

12. Wen W, Meng-Yun C, Peng-Cheng L, Li-Qin H. Specific absorbed fractions of electrons and photons for Rad-HUMAN phantom using Monte Carlo method. Chinese Phys C. 2014;39(7):1-9.

13. Amato E, Lizio D, Baldari S. Absorbed fractions in ellipsoidal volumes for $\beta$-radionuclides employed in internal radiotherapy. Phys Med Biol. 2009;54(13):4171-80.

14. Eckerman KE, Westfall RJ, Ryman JC, Cristy M. Availability of nuclear decay data in electronic form, including beta spectra not previously published. Health Phys. 1994;67(4):338-45.

15. Bouchet LG, Bolch WE, Blanco HP, Wessels BW, Siegel JA, Rajon DA, et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med. 2003;44(7):1113-47.

16. Amato E, Italiano A, Baldari S. An analytical model to calculate absorbed fraction for internal dosimetry with alpha, beta and gamma emitters. Pericol Classe Sci Fis Mat Nat. 2014;92(1):A1.

17. Sgouros G. Dosimetry of internal emitters. J Nucl Med. 2005;46(1):18S-27S.

18. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-7.

19. Bacher K, D’Asseler Y. Evaluation of patient-specific dosimetric methodologies for radionuclide therapy. [Master Thesis]. Ghent, Belgium: Ghent University; 2014.

20. RADAR changes the dosimetry world. The Radiation Dose Assessment Resource. Available at: URL: www.doseinfo-radar.com; Accessed on: 23/1/2017.

21. Asl RG, Parach AA, Nasser S, Moemenzehad M, Zakavi SR, Sadoughi HR. Specific absorbed fractions of internal photon and electron emitters in a human voxel-based phantom: a Monte Carlo study. World J Nucl Med. 2017;16(2):114-21.

22. Interaction of radiation with matter–environmental health. University of Toronto. Available at: URL: https://ehs.utoronto.ca/our-services/radiation-safety/radiation-protection; Accessed on: 8/1/2018.

23. International Commission on Radiation Units and Measurements. Determination of absorbed dose in a patient irradiated by beams of X or gamma rays in radiotherapy procedures. Washington: International Commission on Radiation Units and Measurements (ICRU); 1976.